<DOC>
	<DOCNO>NCT01257061</DOCNO>
	<brief_summary>Atopic dermatitis recurrent pruritic skin disorder significant morbidity impair quality life due specially pruritus physical visible skin lesion . The propose trial evaluate effectiveness clemastine fumarate 1 , 0 mg/g + dexamethasone 0 , 5 mg/g compare dexchlorpheniramine maleate 10 mg/g eczema treatment .</brief_summary>
	<brief_title>Effectiveness Clemastine Fumarate + Dexamethasone Compared Dexchlorpheniramine Maleate Eczema Treatment</brief_title>
	<detailed_description>Study design : â€¢ Double blind , superiority , prospective parallel-group , intend treat trial . Study design : - Experiment duration : 22 day - 2 visit ( day 1,7,15 22 ) - Reducing Eczema Area severity index evaluation - Adverse event evaluation</detailed_description>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Clemastine</mesh_term>
	<mesh_term>Chlorpheniramine</mesh_term>
	<mesh_term>Dexchlorpheniramine</mesh_term>
	<criteria>1 . Patients must able understand study procedure agree participate give write consent . 2 . Patients acute subacute eczema . 3 . Presence symmetric lesion compare side . 1 . Pregnancy risk pregnancy . 2 . Lactation 3 . Use antiinflammatory immunosuppressive drug ( last 30 day prior study ) . 4 . Sunlight exposure last 15 day . 5 . Any pathology past medical condition interfere protocol .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Dermatitis</keyword>
	<keyword>Dermatitis , Atopic</keyword>
</DOC>